June 3, 2024 — HighLife SAS, a medtech company focused on the development of a novel Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from moderate to severe Mitral Regurgitation (MR), announced today that the U.S. Food and Drug Administration (FDA) granted an Investigational Device Exemption (IDE) to initiate a US Pivotal Study with its technology.

May 31, 2024 — Johnson & Johnson announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech.

May 31, 2024 — In the United States there are over 8 million active athletes. Given the rapid expansion of sports cardiology, cardiovascular care teams must understand contemporary care and practice management strategies for all athletes—from the elite to the exercise enthusiast.

May 31, 2024 — CareDx, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced findings from the SHORE (Surveillance HeartCare Outcomes Registry) study, one of the largest heart transplant studies of its kind, published in 

May 30, 2024 — Elixir Medical, a developer of technologies to treat cardiovascular and peripheral disease, announced during the recent Euro PCR 2024 in Paris that the PINNACLE I Trial evaluating the safety and performance of its LithiX Hertz Contact Intravascular Lithotripsy System (IVL) — for treatmen

May 30, 2024 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announced the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Genesis Robotic Magnetic Navigation System.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now